The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: Two international surveys

Journal of Medical Economics

Volumn 17, Issue 10, 2014, Pages 751-761

  Fulcher, Gregory ^a   Singer, Joelle ^b   Castañeda, Rutila ^c   Fraige Filho, Fadlo ^d   Maffei, Laura ^e   Snyman, Jacques ^f   Brod, Meryl ^g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b RABIN MEDICAL CENTER   (Israel)

^c Hospital General Regional No 1 Carlos Mcgregor Sánchez Navarro   (Mexico)

^d FACULDADE DE MEDICINA DO ABC   (Brazil)

^e Consultorios Asociados de Endocrinología e Investigación Clínica Aplicada ^*  (Argentina)

^f Agility Global Health Solutions   (South Africa)

^g Brod Group   (United States)

Author keywords

Daytime; Diabetes; Economics; Healthcare; Nocturnal; Non severe hypoglycemia; Quality of life; Survey

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; ARGENTINA; ARTICLE; AUSTRALIA; BRAZIL; DAYTIME HYPOGLYCEMIA; DIABETIC PATIENT; DRUG DOSE REDUCTION; FEAR; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HEALTH IMPACT ASSESSMENT; HEALTH SURVEY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISRAEL; MAJOR CLINICAL STUDY; MALE; MEXICO; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRODUCTIVITY; QUALITY OF LIFE; SALARY; SLEEP QUALITY; SOCIAL PSYCHOLOGY; SOUTH AFRICA; WORKING TIME; CHEMICALLY INDUCED; DIABETES MELLITUS; ECONOMICS; MIDDLE AGED; PSYCHOLOGY;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 84907285790     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.946992     Document Type: Article

References (41)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared wi th conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
2. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
3. Leiter LA. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-92
4. Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ C ouns 2007;68:10-15
5. Hepburn DA. Symptoms of hypoglycemia. In: Frier BM, Fisher BM, eds. Hypoglycaemia and diabetes: clinical and physiological aspects. London: Edward Arnold, 1993. p 93-103
6. Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic nonsevere hypoglycemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008;6:73
7. Frier BM. How hypoglycemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008;24:87-92
8. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565-72
9. Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
10. Brod M, Pohlman B, Wolden M, et al. Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Qual Life Res 2013;22:997-1004
11. King P, Kong MF, Parkin H, et al. Well-being, cerebral function, and physical fatigue after nocturnal hypoglycemia in IDDM. Diabetes Care 1998;21:341-5
12. Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477-83
13. Fidler C,Elmelund Christensen T,Gillard S., Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs, J Med Econ, 2011, 14, 646-55.
14. Farmer A, Balman E, Gadsby R, et al. Frequency of self-monitoring of blood glucose in patients with type 2 diabetes: association with hypoglycemic events. Curr Med Res Opin 2008;24:3097-104
15. Hansen MV, Pedersen-Bjergaard U, Heller SR, et al. Frequency and motives of blood glucose self-monitoring in type 1 diabetes. Diabetes Res Clin Pract 2009;85:183-8
16. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57: 3169-76
17. Donnelly LA, Morris AD, Frier BM, et al; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabe t Med 2005;22:749-55
18. Lü ddeke HJ, Sreenan S, Aczel S, et al; PREDICTIVE Study Group. PREDICTIVEa global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline chara cteristics and predictors of hypoglycemia from the European cohort. Diabetes Obes Metab 2007;9:428-34
19. International Diabetes Federation. IDF Diabetes Atlas. 5th edn. Brussels, Belgium: International Diabetes Federation, 2012. http://www.idf.org/diabetesatlas. Accessed November 7, 2013
20. UK Hypoglycaemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
21. Bodmer M, Meier C, Krähenbühl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-contr ol analysis. Diabetes Care 2008;31:2086-91
22. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Socie ty. Diabetes Care 2013;36:1384-95
23. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-co untry survey. J Med Econ 2012;15:77-86
24. Brod M, Wolden M, Christensen T, et al. A nine country study of the burden of non-severe nocturnal hypoglycemic events on diabetes management and daily function. Diabetes Obes Metab 2013;15:546-57
25. Marrett E, Radican L, Davies MJ, et al. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011;4:251
26. Willis WD, Diago-Cabezu do JI, Madec-Hily A, et al. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey. Expert Rev Pharmacoecon Outcomes Res 2013; 13:123-30
27. Brito-Sanfiel M, Diago-Cabezudo J, Calderon A. Economic impact of hypoglycemia on healthcare in Spain. Expert Rev Pharmacoecon Outcomes Res 2010;10:649-60
28. Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycemia in three European countries. J Med Econ 2009;12:281-90
29. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care 2002;25:2109-10.
30. Leese GP, Wang J, Broomhall J, et al; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80
31. Joo EY, Yoon CW, Koo DL, et al. Adverse effects of 24 hours of sleep deprivation on cognition and stress hormones. J Clin Neurol 2012;8:146-50
32. Luyster FS, Strollo Jr. PJ,, Zee PC, et al; Boards of Directors of the American Academy of Sleep Medicine and the Sleep Research Society. Sleep: a health imperative. Sleep 2012;35:727-34
33. Kovacs Burns K, Nicolucci A, Holt RI, et al; DAWN2 Study Group. Diabetes Attitudes, Wishes and Needs second study (DAWN2TM): cross-national benchmarking i ndicators for family members living with people with diabetes. Diabet Med 2013;30:778-88
34. Irvine AA,Cox D Gonder-Frederick L., Fear of hypoglycemia: relationship to physical and psychological symptom s in patients with insulin-dependent diabetes mellitus, Health Psychol, 1992, 11, 135-8.
35. Crasto W, Jarvis J, Khunti K, et al. Multifactorial intervention in individuals with type 2 diabetes and m icroalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Res Clin Pract 2011;93:328-36
36. Gagliardino JJ, Etchegoyen G; PENDID-LA Research Group. A model e ducational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA). Diabetes Care 2001;24:1001-7
37. Pramming S, Thorsteinsson B, Bendtson I, et al. Symptomatic hypoglycemia in 411 type 1 diabetic patients. Diabet Med 1991;8:217-22
38. Barquera S, Campos-Nonato I, Aguilar-Salinas C, et al. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Global Health 2013;9:3
39. Arredondo A, Reyes G. Health disparities from economic burden of diabetes in middle-income countries: evidence from Mé xico. PLoS One 2013;8:e68443
40. Bertoldi AD, Kanavos P, Franç a GV, et al. Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review. Global Health 2013;9:62
41. Caporale JE, Elgart JF, G agliardino JJ. Diabetes in Argentina: cost and management of diabetes and its complications and challenges for health policy. Global Health 2013;9:54